Rocket Pharmaceuticals (RCKT) Stock Forecast, Price Target & Predictions
RCKT Stock Forecast
Rocket Pharmaceuticals stock forecast is as follows: an average price target of $47.33 (represents a 140.87% upside from RCKT’s last price of $19.65) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
RCKT Price Target
The average price target for Rocket Pharmaceuticals (RCKT) is $47.33 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $69.00 to $34.00. This represents a potential 140.87% upside from RCKT's last price of $19.65.
RCKT Analyst Ratings
According to 8 Wall Street analysts, Rocket Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RCKT stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Rocket Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 02, 2024 | Richard Law | Goldman Sachs | $39.00 | $26.72 | 45.96% | 98.47% |
| Oct 03, 2022 | - | Raymond James | $34.00 | $15.96 | 113.03% | 73.03% |
| Aug 09, 2022 | - | Raymond James | $24.00 | $15.17 | 58.21% | 22.14% |
| Aug 12, 2021 | Esther Rajavelu | UBS | $69.00 | $30.80 | 124.03% | 251.15% |
The latest Rocket Pharmaceuticals stock forecast, released on Apr 02, 2024 by Richard Law from Goldman Sachs, set a price target of $39.00, which represents a 45.96% increase from the stock price at the time of the forecast ($26.72), and a 98.47% increase from RCKT last price ($19.65).
Rocket Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $39.00 |
| Last Closing Price | $19.65 | $19.65 | $19.65 |
| Upside/Downside | -100.00% | -100.00% | 98.47% |
In the current month, the average price target of Rocket Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rocket Pharmaceuticals's last price of $19.65. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 02, 2024 | Goldman Sachs | - | Neutral | Initialise |
| Sep 13, 2023 | Needham | Buy | Buy | Hold |
| Feb 01, 2023 | Morgan Stanley | - | Overweight | Initialise |
| Dec 06, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Oct 03, 2022 | Chardan Capital | Buy | Buy | Hold |
| Oct 03, 2022 | Raymond James | Outperform | Outperform | Hold |
| Sep 30, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Sep 30, 2022 | Evercore ISI | Outperform | Outperform | Hold |
| Sep 27, 2022 | UBS | Buy | Buy | Hold |
| Aug 09, 2022 | Raymond James | Outperform | Outperform | Hold |
Rocket Pharmaceuticals's last stock rating was published by Goldman Sachs on Apr 02, 2024. The company Initialise its RCKT rating from "null" to "Neutral".
Rocket Pharmaceuticals Financial Forecast
Rocket Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.31M | - |
| Avg Forecast | $182.22M | $147.04M | $120.94M | $85.91M | $26.88M | $14.65M | $20.06M | $2.49M | $11.15M | $564.31K | $1.84M | - | $10.31M | $111.11K |
| High Forecast | $182.22M | $147.04M | $120.94M | $85.91M | $26.88M | $14.65M | $20.06M | $2.49M | $11.15M | $564.31K | $1.84M | - | $19.56M | $111.11K |
| Low Forecast | $182.22M | $147.04M | $120.94M | $85.91M | $26.88M | $14.65M | $20.06M | $2.49M | $11.15M | $564.31K | $1.84M | - | $1.05M | $111.11K |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 8 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | - |
Rocket Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 2 analysts is -, with a low forecast of -, and a high forecast of -. RCKT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $10.31M (Dec 23).
Rocket Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 8 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-73.26M | $-63.95M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict RCKT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Rocket Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Rocket Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 8 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-63.05M | $-64.36M |
| Avg Forecast | $-1.80M | $-19.14M | $-29.79M | $-47.52M | $-61.29M | $-66.83M | $-70.10M | $-71.51M | $-71.69M | $-70.47M | $-67.68M | $-62.92M | $-72.66M | $-74.81M |
| High Forecast | $-1.80M | $-19.14M | $-29.79M | $-47.52M | $-61.29M | $-66.83M | $-70.10M | $-71.51M | $-71.69M | $-61.32M | $-67.68M | $-62.92M | $-67.21M | $-74.81M |
| Low Forecast | $-1.80M | $-19.14M | $-29.79M | $-47.52M | $-61.29M | $-66.83M | $-70.10M | $-71.51M | $-71.69M | $-76.88M | $-67.68M | $-62.92M | $-79.01M | $-74.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.86% |
Rocket Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RCKT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Rocket Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 8 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $21.54M | $19.05M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Rocket Pharmaceuticals's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RCKT last annual SG&A of $21.54M (Dec 23).
Rocket Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 8 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.94 |
| Avg Forecast | $-0.02 | $-0.20 | $-0.32 | $-0.51 | $-0.65 | $-0.71 | $-0.75 | $-0.76 | $-0.76 | $-0.75 | $-0.72 | $-0.67 | $-0.78 | $-0.80 |
| High Forecast | $-0.02 | $-0.20 | $-0.32 | $-0.51 | $-0.65 | $-0.71 | $-0.75 | $-0.76 | $-0.76 | $-0.65 | $-0.72 | $-0.67 | $-0.72 | $-0.80 |
| Low Forecast | $-0.02 | $-0.20 | $-0.32 | $-0.51 | $-0.65 | $-0.71 | $-0.75 | $-0.76 | $-0.76 | $-0.82 | $-0.72 | $-0.67 | $-0.85 | $-0.80 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 1.18% |
According to undefined Wall Street analysts, Rocket Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RCKT previous annual EPS of $NaN (undefined).
Rocket Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| QURE | uniQure | $5.66 | $53.67 | 848.23% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| RGNX | REGENXBIO | $12.84 | $38.00 | 195.95% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| RCKT | Rocket Pharmaceuticals | $19.65 | $47.33 | 140.87% | Buy |
| STRO | Sutro Biopharma | $4.50 | $10.80 | 140.00% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| SLDB | Solid Biosciences | $7.93 | $17.50 | 120.68% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| MIRM | Mirum Pharmaceuticals | $41.12 | $54.50 | 32.54% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| RYTM | Rhythm Pharmaceuticals | $49.62 | $38.33 | -22.75% | Buy |
RCKT Forecast FAQ
Is Rocket Pharmaceuticals a good buy?
Yes, according to 8 Wall Street analysts, Rocket Pharmaceuticals (RCKT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of RCKT's total ratings.
What is RCKT's price target?
Rocket Pharmaceuticals (RCKT) average price target is $47.33 with a range of $34 to $69, implying a 140.87% from its last price of $19.65. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Rocket Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for RCKT stock, the company can go up by 140.87% (from the last price of $19.65 to the average price target of $47.33), up by 251.15% based on the highest stock price target, and up by 73.03% based on the lowest stock price target.
Can Rocket Pharmaceuticals stock reach $30?
RCKT's average twelve months analyst stock price target of $47.33 supports the claim that Rocket Pharmaceuticals can reach $30 in the near future.
What are Rocket Pharmaceuticals's analysts' financial forecasts?
Rocket Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.07M (high $64.07M, low $64.07M), average EBITDA is $0 (high $0, low $0), average net income is $-270M (high $-270M, low $-270M), average SG&A $0 (high $0, low $0), and average EPS is $-2.877 (high $-2.877, low $-2.877). RCKT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $536.12M (high $536.12M, low $536.12M), average EBITDA is $0 (high $0, low $0), average net income is $-98.255M (high $-98.255M, low $-98.255M), average SG&A $0 (high $0, low $0), and average EPS is $-1.048 (high $-1.048, low $-1.048).
Did the RCKT's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Dec 2023), Rocket Pharmaceuticals's revenue was $10.31M, beating the average analysts' forecast of $10.31M by 0%. The company's EBITDA was $-73.257M, beating the average prediction of $0 by 0%. Rocket Pharmaceuticals's net income was $-63.051M, missing the average estimation of $-72.658M by -13.22%. The company's SG&A was $21.54M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-0.0008, missing the average prediction of $-0.778 by -99.90%